Kisspeptin-10 Results: What Studies Measured and When
What published studies measured for Kisspeptin-10, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| LH, FSH and testosterone (acute) | Acute kisspeptin-10 infusions raised LH, FSH and testosterone dose-dependently versus vehicle (P < .0001). | Human RCTn = 15 | European journal of endocrinology 2026, PMID 42549827 |
| Continuous 5-day infusion | After 5 days of continuous infusion testosterone stayed elevated but gonadotropins matched vehicle. | Human RCTn = 15 | European journal of endocrinology 2026, PMID 42549827 |
| Intermittent 12-day dosing | Daily 8-hour infusions over 12 days sustained gonadotropin increases. | Human RCTn = 15 | European journal of endocrinology 2026, PMID 42549827 |
| Ovulation after MVT-602 | Ovulation within 5 days: 100% (3 ug), 88% (1 ug), 82% (0.3 ug), 75% (0.1 ug) vs 60% on placebo. | Human RCT | Fertility and sterility 2024, PMID 37925096 |
| Brain response to erotic stimuli | Kisspeptin changed brain responses to erotic and attraction stimuli on fMRI; no symptom efficacy outcome in abstract. | Human RCTn = 40 | JAMA network open 2022, PMID 36287566 |
| Bone formation marker | Total osteocalcin rose a maximum of 20.3% after kisspeptin (P = .021). | Human RCTn = 26 | The Journal of clinical endocrinology and metabolism 2022, PMID 35244717 |
| Limbic brain activity and mood | Kisspeptin enhanced limbic brain activity in response to sexual and couple-bonding stimuli. | Human RCTn = 29 | The Journal of clinical investigation 2017, PMID 28112678 |
| Testosterone during infusion | At 4 ug/kg/h for 22.5 h, LH rose from 5.4 to 20.8 IU/liter and testosterone from 16.6 to 24.0 nmol/liter. | Human controlled trial | The Journal of clinical endocrinology and metabolism 2011, PMID 21632807 |
| Twice-weekly dosing for 8 weeks | Twice-weekly KP-54 for 8 weeks kept reproductive hormones higher than saline. | Human RCT | Clinical pharmacology and therapeutics 2010, PMID 20980998 |
| Tachyphylaxis with repeated dosing | LH and FSH responses fell sharply by day 14 of twice-daily injections (LH +2.5 IU/liter, FSH +0.5 IU/liter). | Human RCT | The Journal of clinical endocrinology and metabolism 2009, PMID 19820030 |
| LH by cycle phase | Kisspeptin raised LH most in the preovulatory phase and least in the follicular phase. | Human controlled trial | The Journal of clinical endocrinology and metabolism 2007, PMID 17635940 |
| Egg maturation and pregnancy | Biochemical pregnancy 40% (21/53); clinical pregnancy 23% (12/53). | Human uncontrolled trialn = 53 | The Journal of clinical investigation 2014, PMID 25036713 |
| Pulsatile LH restored | Continuous kisspeptin infusion restored gonadotropin pulsatility in patients with NKB-pathway mutations. | Human uncontrolled trial | Neuroendocrinology 2013, PMID 22377698 |
| Sexual dimorphism of response | Kisspeptin-10 raised gonadotropins in men and in preovulatory women but not in follicular-phase women. | Human uncontrolled trial | The Journal of clinical endocrinology and metabolism 2011, PMID 21976724 |
| Hepatic de novo lipogenesis | Kisspeptin reduced hepatic de novo lipogenesis of free fatty acids in steatotic mouse livers. | Animal · mouse (not a human result) | Cells 2025, PMID 40862768 |
| Hepatic steatosis | Deleting hepatic Kiss1r worsened steatosis; stimulating KISS1R protected against steatosis and reduced fibrosis in mice. | Animal · mouse (not a human result) | The Journal of clinical investigation 2022, PMID 35349482 |
| Liver antioxidant enzymes | Kisspeptin raised liver SOD and catalase activity (p < 0.05) in rats. | Animal · rat (not a human result)n = 24 | Cell biochemistry and function 2010, PMID 20517893 |
- This page covers kisspeptin-10, but most controlled human trials used kisspeptin-54 or analogues (MVT-602, TAK-448); each study names the form used. Kisspeptin-10 itself has human data only in healthy men (PMIDs 21632807, 42549827) and a small mixed-sex study (21976724).
- Half-lives given are for analogues (MVT-602, TAK-448), not native kisspeptin-10; no native kisspeptin-10 half-life was found.
- Chronic dosing causes desensitisation: twice-daily kisspeptin-54 produced tachyphylaxis in women with hypothalamic amenorrhea (PMID 19820030); continuous 5-day kisspeptin-10 in men did not sustain gonadotropins (PMID 42549827).
- No human trial of kisspeptin in menopausal or perimenopausal women was found in PubMed (a cycle-phase study, 17635940, was in premenopausal women).
- For liver health there are only mouse and rat studies (3 selected); no human liver trial was found.
- No trial of kisspeptin in men with hypogonadism was found; the testosterone evidence is healthy-volunteer physiology.
- Kisspeptin is not FDA approved. Study 28112678 does not state dose or route.
- Results in 20980998 and 19820030 are small (n = 5 per group in the latter).
Typical timeline
When measurable changes appeared in studies of Kisspeptin-10: not reported in study abstracts (PubMed search, 2 Oct 2026).
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does Kisspeptin-10 take to work?
The study abstracts we summarised for Kisspeptin-10 do not report when outcomes were measured (PubMed search, 2 Oct 2026).
Do you show Kisspeptin-10 before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on Kisspeptin-10
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.For testosteroneWhat research says about Kisspeptin-10 for testosterone.For menopauseWhat research says about Kisspeptin-10 for menopause.
Sources
- 1Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.European journal of endocrinology · 2026PMID 42549827Accessed 2 Oct 2026
- 2Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals.Fertility and sterility · 2024PMID 37925096Accessed 2 Oct 2026
- 3Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial.JAMA network open · 2022PMID 36287566Accessed 2 Oct 2026
- 4Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men.The Journal of clinical endocrinology and metabolism · 2022PMID 35244717Accessed 2 Oct 2026
- 5Kisspeptin modulates sexual and emotional brain processing in humans.The Journal of clinical investigation · 2017PMID 28112678Accessed 2 Oct 2026
- 6Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men.The Journal of clinical endocrinology and metabolism · 2011PMID 21632807Accessed 2 Oct 2026
- 7Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproductive hormones in women with hypothalamic amenorrhea.Clinical pharmacology and therapeutics · 2010PMID 20980998Accessed 2 Oct 2026
- 8Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.The Journal of clinical endocrinology and metabolism · 2009PMID 19820030Accessed 2 Oct 2026
- 9Kisspeptin-54 stimulates gonadotropin release most potently during the preovulatory phase of the menstrual cycle in women.The Journal of clinical endocrinology and metabolism · 2007PMID 17635940Accessed 2 Oct 2026
- 10Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.The Journal of clinical investigation · 2014PMID 25036713Accessed 2 Oct 2026
- 11Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: physiological, pathophysiological and therapeutic implications.Neuroendocrinology · 2013PMID 22377698Accessed 2 Oct 2026
- 12The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans.The Journal of clinical endocrinology and metabolism · 2011PMID 21976724Accessed 2 Oct 2026
- 13Kisspeptin Mitigates Hepatic De Novo Lipogenesis in Metabolic Dysfunction-Associated Steatotic Liver Disease.Cells · 2025PMID 40862768Accessed 2 Oct 2026
- 14Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.The Journal of clinical investigation · 2022PMID 35349482Accessed 2 Oct 2026
- 15Direct and indirect effects of kisspeptin on liver oxidant and antioxidant systems in young male rats.Cell biochemistry and function · 2010PMID 20517893Accessed 2 Oct 2026
- 16PubMed search: ("kisspeptin-10"[tiab] OR "kisspeptin 10"[tiab]) AND humans[mh] (110 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: (kisspeptin[tiab]) AND humans[mh] AND (randomized controlled trial[pt] OR clinical trial[pt]) (54 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: kisspeptin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) AND humans[mh] (13 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: kisspeptin[tiab] AND humans[mh] AND (men[tiab] OR male[tiab]) AND (testosterone[tiab] OR hypogonadism[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: kisspeptin[tiab] AND (menopaus*[tiab] OR postmenopaus*[tiab]) (89 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: kisspeptin[tiab] AND (liver[tiab] OR NAFLD[tiab] OR hepatic[tiab]) (68 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.